Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1981-2000 of 2,251 trials

Non-Small Cell Lung Cancer: Sigvotatug Vedotin with Pembrolizumab

We are studying a new treatment combining sigvotatug vedotin with pembrolizumab for patients with advanced non-small cell lung cancer that has high PD-L1 levels. The goal is to see if this combination works better than pembrolizumab alone.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Cardiac Amyloidosis: PET Imaging with Vizamyl®

We are studying a new imaging tracer to see how effectively it detects amyloid deposits in the hearts of patients with cardiac amyloidosis. This research may help improve diagnosis and understanding of the disease.

Cardiac Amyloidosis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiology

Turner Syndrome: Estrogen Therapy Comparison

We are studying the long-term effects of oral versus transdermal estrogen replacement therapy in women with Turner syndrome. This research aims to clarify health risks and benefits associated with each treatment method.

Turner's Syndrome6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyInternal Medicine

Metastatic Breast Cancer: Targeted Treatment Based on Genetic Analysis

We are studying whether targeted therapies guided by genetic testing can improve survival for patients with metastatic breast cancer compared to standard chemotherapy. This trial aims to personalize treatment based on individual genetic profiles.

Metastatic Breast CancerEfficacy phase (II)No PlaceboStandard MedicinesOncology

Colorectal Cancer: Telisotuzumab Adizutecan Treatment

We are studying a new treatment for adults with colorectal cancer who have positive circulating tumor DNA but no visible disease. The goal is to see if this treatment improves disease-free survival compared to standard care.

Colorectal Cancer6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

HER2-Positive Cancer: Trastuzumab Deruxtecan Study

We are exploring a new treatment for HER2-positive cancer using a blood test to monitor changes in HER2 status. This study aims to improve treatment personalization and assess the safety of the new medication.

Metastatic HER2-Positive Breast CancerEfficacy phase (II)No PlaceboStandard MedicinesOncology

Septic Shock: Mesenchymal Stem Cells Treatment

We are studying whether early administration of mesenchymal stem cells can improve organ function in patients with septic shock. This trial compares the effects of MSCs to standard treatment in intensive care.

Severe Septic Shock>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyInfectious DiseasesInternal MedicinePulmonology

Prostate Cancer: Ebastine with Docetaxel or Cabazitaxel

We are studying a new treatment combining ebastine with either docetaxel or cabazitaxel for men with metastatic castration-resistant prostate cancer. The goal is to evaluate how this combination affects cancer markers and PSA levels.

Hormone-Refractory Prostate Cancer3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyUrology

Opioid-Induced Respiratory Depression: Naloxone and Nalmefene Study

We are studying how well naloxone and nalmefene can reverse breathing problems caused by opioids in both new and long-term users. This research aims to improve treatment options for respiratory depression in real-life settings.

Healthy VolunteersOpioid Use Disorder>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal MedicineOtolaryngologyPulmonology

Schizophrenia: Cariprazine for Cognitive Function

We are studying how cariprazine affects cognitive functioning in patients with schizophrenia who need changes to their current treatment. The trial will also look at overall quality of life and any side effects.

Acute Schizophrenia6-12 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPsychiatry

Penile and Tongue Cancer: New Imaging Technique

We are evaluating a new fluorescent imaging method to help surgeons visualize tumors and lymph node spread during surgery for penile and tongue cancer. This study aims to improve detection and assess any side effects.

Penile CancerTongue Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyUrology

Cardiac Arrest and Ventricular Fibrillation: RIME-IVF Study

We are investigating how beta-blocker treatment affects patients with idiopathic ventricular fibrillation and those who have had out-of-hospital cardiac arrests. We also aim to understand the quality of life for survivors of cardiac arrest.

Idiopathic Ventricular FibrillationMonitoring phase (IV)No PlaceboStandard MedicinesCardiology

Orthopedic Surgery: Intraoperative Methadone Study

We are investigating whether methadone can reduce pain and improve satisfaction after orthopedic surgery compared to standard pain relief methods. This study aims to ensure safety while managing postoperative pain effectively.

Orthopedic Surgery>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOrthopedics and Traumatology

Acute Myeloid Leukemia: Eganelisib Treatment Study

We are studying the safety and tolerability of eganelisib alone and with cytarabine in patients with relapsed or refractory acute myeloid leukemia. This trial aims to find the best dose and evaluate how well the treatment works.

Relapsed/Refractory Acute Myeloid LeukemiaHigher-Risk Myelodysplastic SyndromesSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Locally Advanced Rectal Cancer: FOLFOX Before Surgery

We are comparing the effects of chemotherapy before surgery to risk-adapted chemotherapy after surgery for patients with locally advanced rectal cancer. Our goal is to see which approach may lead to better disease-free survival and fewer complications.

Locally Advanced Rectal Cancer≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Immunotherapy for MSI/dMMR Tumors: Pembrolizumab Study

We are studying the effects of pembrolizumab in patients with untreated localized MSI/dMMR tumors or EBV+ gastric cancer. The goal is to see if this treatment improves outcomes before and after surgery.

MSI/dMMR Tumors and EBV+ Gastric Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

ABO-101 for Primary Hyperoxaluria Type 1

We are testing a new treatment, ABO-101, to see if it is safe and well-tolerated in people with Primary Hyperoxaluria Type 1. The study will also explore how the body reacts to the treatment.

Primary Hyperoxaluria>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteEndocrinologyNephrology

Lung Cancer: RMC-6236 vs. Docetaxel

We are studying a new treatment for patients with advanced lung cancer who have RAS mutations. The goal is to see if RMC-6236 works better than the standard treatment, docetaxel.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

EGFR-Mutated Lung Cancer: ERIS Study

We are exploring the best sequence of EGFR-inhibitors for patients with EGFR-mutated lung cancer. The study also examines treatment effects, side effects, and quality of life.

EGFR-Mutated Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncology

HER2-Positive Breast Cancer: New Treatment Without Chemotherapy

We are studying a combination of trastuzumab, pertuzumab, and tucatinib for patients with stage II-III HER2-positive breast cancer. The goal is to evaluate the safety and initial effectiveness of this chemotherapy-free approach.

HER2 Positive Breast Cancer1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology